Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference2%
- Check24 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no other page content or data appears to be altered.SummaryDifference0.1%
- Check39 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed. No substantive changes to core content, pricing, stock, or other critical data.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check53 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new entries related to various chemical compounds and treatments for malignant epithelial tumors of the ovary. Notably, the revision number has been updated to v3.0.0.SummaryDifference3%
- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.